Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Adenylate kinase 4 pseudogene 2 (AK4P2) is classified as a pseudogene, meaning it is a non-functional genomic sequence similar to but distinct from the functional AK4 gene. Unlike the canonical AK4 gene, which encodes a mitochondrial enzyme involved in nucleotide metabolism, AK4P2 does not encode a protein and has no known biological activity or therapeutic relevance[4][5]. Pseudogenes like AK4P2 typically arise from duplication or retrotransposition events and do not contribute to enzymatic or signaling pathways. There are no documented roles in disease, no known molecular interactions, and no evidence supporting its status as a drug target. It is maintained in the genome primarily as an evolutionary remnant[4][5]. This is not a therapeutic target (enzyme, receptor, transporter, etc.) and should not be used in contexts seeking functional or druggable targets. The query is "incorrect" in the context of therapeutic discovery, as AK4P2 is a non-coding pseudogene[4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Adenylate kinase 4 pseudogene 2 (AK4P2).